13.75
-0.03
(-0.22%)
Real-time:
11:43AM EDT
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 13.69 - 13.84 |
| 52 week | 9.37 - 14.80 |
| Open | 13.70 |
| Vol / Avg. | 10.49M/14.98M |
| Mkt cap | 7.03B |
| P/E | - |
| Div/yield | - |
| EPS | -0.62 |
| Shares | 511.16M |
| Beta | 0.94 |
| Inst. own | 66% |
Events
Jul 22, 2013
Q2 2013 Elan Corporation, PLC Earnings Release
Jun 17, 2013
Elan Corporation, PLC Extraordinary Shareholder Meeting
Jun 5, 2013
Elan Corporation, PLC at Jefferies Global Healthcare Conference -
May 20, 2013
Elan Corporation PLC Corporate Update Conference Call -
May 13, 2013
Elan Corporation PLC and Theravance Inc Enter Into a $1.0 Billion Royalty Participation Agreement Conference Call
Apr 24, 2013
Q1 2013 Elan Corporation, PLC Earnings Conference Call -
Apr 22, 2013
Q1 2013 Elan Corporation PLC Earnings Release
Apr 12, 2013
Elan Corporation, PLC Extraordinary Shareholder Meeting
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -36400.00% | -186350.00% |
| Operating margin | -33450.00% | -226800.00% |
| EBITD margin | - | -95900.00% |
| Return on average assets | -17.95% | -21.96% |
| Return on average equity | -44.91% | -52.49% |
| Employees | 245 | - |
| Carbon Disclosure Rating | - | 6/100 |
Address
Treasury Building Lower Grand Canal Street, Dublin 2
DUBLIN, 2
Ireland
+353-1-7094000 (Phone)
+353-1-7094700 (Fax)
DUBLIN, 2
Ireland
+353-1-7094000 (Phone)
+353-1-7094700 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
About Company - Wikipedia
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Elan Corporation, plc (Elan), is a biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. On February 6, 2013, the Company announced that it has entered into an asset purchase agreement with Biogen Idec to transfer to Biogen Idec all Tysabri IP and other assets related to Tysabri. As of 31 December 2012, there were approximately 72,700 patients on Tysabri therapy worldwide. On December 20, 2012, the Company completed the separation of a substantial portion of its drug discovery business platform (the Prothena Business) into a new, publicly traded company, Prothena Corporation, plc (Prothena).
Officers and directors
| G. Kelly Martin | Chief Executive Officer, Executive Director | |
| Nigel Clerkin | Chief Financial Officer, Executive Vice President | |
| Hans Peter Hasler | Chief Operating Officer | |
| William F. Daniel | Executive Vice President, Company Secretary | |
| Fabiana Lacerca-Allen | Senior Vice President, Chief Compliance Officer | |
| Guriq Basi | Chief Science & Technology Officer | |
| Grainne McAleese | Principal Accounting Officer, Group Controller | |
| John Given | General Counsel | |
| Menghis Bairu M.D. | Chief Medical Officer, Head - Development | |
| Mary Sheahan | Head - Human Resources, IT, Facilities and Portfolio Assessment Management |